AI Summary
This article discusses the results of the first sham-controlled trial of atrial fibrillation ablation with pulmonary vein isolation, showing a placebo-resistant benefit. However, the author notes that questions still remain about how this treatment works.
The first sham-controlled trial of atrial fibrillation ablation with pulmonary vein isolation shows a placebo-resistant benefit, but questions remain about how it works, writes John Mandrola, MD.
theheart.org on Medscape